Geode Capital Management LLC Has $1.29 Million Stock Holdings in Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Geode Capital Management LLC raised its position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 3.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 686,153 shares of the company’s stock after acquiring an additional 19,843 shares during the period. Geode Capital Management LLC owned about 2.20% of Actinium Pharmaceuticals worth $1,290,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ATNM. Rhumbline Advisers increased its position in shares of Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after purchasing an additional 7,525 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in Actinium Pharmaceuticals during the second quarter worth $92,000. Bank of New York Mellon Corp increased its holdings in Actinium Pharmaceuticals by 28.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after buying an additional 19,035 shares during the period. Renaissance Technologies LLC bought a new stake in Actinium Pharmaceuticals in the 2nd quarter valued at $142,000. Finally, Interchange Capital Partners LLC acquired a new position in shares of Actinium Pharmaceuticals in the 3rd quarter valued at $37,000. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Price Performance

ATNM stock opened at $1.31 on Friday. The company’s fifty day simple moving average is $1.43. Actinium Pharmaceuticals, Inc. has a fifty-two week low of $1.10 and a fifty-two week high of $10.24. The firm has a market cap of $40.87 million, a PE ratio of -0.94 and a beta of 0.12.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ATNM shares. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Actinium Pharmaceuticals in a research report on Friday, November 15th. StockNews.com lowered Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Finally, Stephens reiterated an “overweight” rating and issued a $5.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).